Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ERS Genomics
ERS Genomics
Activities:
Manufacturing
Research & Development
Analysis
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Cell & Gene Therapy
CRISPR patent upheld by CNIPA
Patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge
Regulatory
Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office
Patent JP6692856 upheld for second time in response to invalidation challenge
Research & Development
CET licenses CRISPR/Cas9 portfolio from ERS Genomics
ERS was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier
Finance
ERS Genomics and Japan SLC sign CRISPR/Cas9 license agreement
ERS Genomics holds an exclusive license from Dr Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform
Regulatory
ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement
ERS Genomics holds the exclusive license from co-founder Dr Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform
Regulatory
ERS Genomics licenses CRISPR gene editing tech to Otsuka
Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan
Finance
ERS Genomics appoints Jon Kratochvil as VP Business Development
He is an inventor on more 40 patents and patent applications
Subscribe now